Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.32 |
| ▸ | HTR2A | P28223 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.31 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26262569 | 0.80 | NOS3 (0.41) | KDM4ETP53CD274 | |
| SCHEMBL4826754 | 0.80 | KDM4E (0.40) | KDM4ETP53CD274SLC6A4HTR2A | |
| SCHEMBL4837374 | 0.80 | KDM4E (0.37) | KDM4ETP53SLC6A4HTR2AKCNH2 | |
| SCHEMBL10272045 | 0.76 | NOS3 (0.39) | KDM4ETP53HSP90AB1HTR2AKCNH2 | |
| SCHEMBL7111691 | 0.75 | SMN1; SMN2 (0.38) | KDM4EHSP90AB1 | |
| SCHEMBL19534266 | 0.75 | ADH1B (0.34) | — | |
| SCHEMBL24270155 | 0.74 | KDM4E (0.44) | KDM4ETP53CD274KMT2A | |
| SCHEMBL19534265 | 0.71 | NOTUM (0.40) | KDM4ETP53HSP90AB1KMT2A | |
| SCHEMBL21434179 | 0.71 | ADORA2A (0.41) | HSP90AB1 | |
| SCHEMBL29411251 | 0.71 | NOTUM (0.40) | KDM4EHSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442692-B2 | Indanyl-piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2008-10-28 | — | — | US | disclosed |
| EP-1707564-B1 | Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2007-09-12 | — | — | EP | disclosed |
| US-20060223830-A1 | Indanyl-piperazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-10-05 | — | — | US | disclosed |
| WO-2006103342-A2 | INDANYL-PIPERAZINE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2006-10-05 | — | — | WO | disclosed |
| EP-1707564-A2 | Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2006-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223830-A1 | Indanyl-piperazine compounds | HTR4, NR4A1, NR4A3 | KDM4E 1559/4885TP53 3984/4885CD274 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.